Michael Kaplan, who runs the private practice Long Island Weight Loss Institute in Port Jefferson, said, "I'm very much against the compounded products." Kaplan, who also runs other locations throughout Nassau and Suffolk counties, said the compounded drugs, or off-label versions of GLP-1s, have not been approved by the U.S
Blue light-activated riboflavin phosphate promotes collagen crosslinking to modify the properties of connective tissues
Sex at the interface: the origin and impact of sex differences in the developing human placenta
#ClinicalPharmacology #RespiratoryMedicine #Asthma #COPD #MedicationSafety #PatientEducation #EvidenceBasedMedicine #Healthcare #InhalerTechnique #laurelpolyclinic To view or add a comment, sign in A quieter story from this month deserves clinicians' attention: on July 1, Medicare began covering an obesity medication through the new GLP-1 Bridge program, the first time it has paid for a weight loss drug since Part D excluded that category in 2006
GHK-Cu remains primarily a research-stage compound